Abstract
Introduction
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, and it is associated with higher morbidity and mortality. However, treatment options for AF are still limited and often not effective. Studies have indicated that statins might be associated with a decreased risk of occurrence or recurrence of AF. The following review summarizes the key findings of the recently published studies.
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with subsequent deterioration of atrial mechanical function (Andrade et al., 2014) . AF is the most common clinically significant cardiac arrhythmia, and it is an independent risk factor for cardiovascular (CV) morbidity and mortality (Benjamin et al., 1998) . Patients with AF have a five-fold higher risk of stroke and two-fold higher risk of death (Friberg et al., 2010; Chamberlain et al., 2011) . Nowadays, AF is one of the most important public health issues, which leads to increased health care costs in western countries (Zoni-Berisso et al., 2014).
Based on the available data, risk factors involved in the development of AF include sex, age, body mass index (BMI), total cholesterol (TC), hypertension and diabetes mellitus (DMt2) (Magnani et al., 2011; January et al., 2014) . Moreover, it has been indicated that inflammation might also play a significant role in the development of AF (Guo et al., 2012) ; therefore it has been suggested that statins might be effective anti-AF drugs.
Statins in postoperative AF
AF is the most common postoperative complication after cardiothoracic and non-cardiothoracic surgery (Banach et al. 2007 (Banach et al. & 2010 . Frequency of postoperative atrial fibrillation (POAF) despite implementation of several drug therapies might reach even 65% (Mathew et al., 2004; Patti et al., 2006) . The mechanism for the occurrence of postoperative AF has been postulated to be associated with increased levels of systemic inflammatory markers and oxidative stress parameters preoperatively (Aviles et al., 2003) . Several studies have indicated an association between AF and various inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP) and TC (Guo et al., 2012; Shi et al., 2015) . Other studies have also suggested a role of preoperative arrhythmias as a predictor of POAF (Banach et al. 2007 ).
Statins are the most effective drugs to treat hypercholesterolemia (Hobbs et al. 2016 ). Available studies indicated that statin therapy might be effective in protecting against AF in acute coronary syndrome (ACS) (Zhou et al., 2013 ) and coronary artery disease (CAD) (Zhou et al., 2013a) , but the strongest evidence for AF prevention by statin intake is in post-cardiac surgery patients (Kuhn et al., 2014).
The mechanism whereby statin might prevent AF has not been fully clarified, but it might involve the pleiotropic effects of anti-inflammatory and antioxidant activities, prevention of endothelial dysfunction and neurohormonal activation (Adam et al., 2008 (Bokeriya et al., 2016) . Statin treatment decreased the frequency of AF soon after coronary bypass surgery (OR 0.481 at 95% CI 0.345-0.672; p < 0.001) and decreased the frequency of cerebral circulation disorders (OR 0.067 at 95% CI 0.037-0.121; p < 0.001) (Bokeriya et al., 2016) . Efficacy of preoperative statin therapy in patients who underwent CABG was also confirmed in a retrospective study by Bockeria et al. (2016) .
In other types of cardiac surgery, such as isolated cardiac valve surgery, Bolesta and Kong (2015) indicated that pre-operative statin use was not associated with a decreased incidence of POAF. The results of this retrospective study of 244 adults may be associated with the fact that the duration of preoperative statin use and the statin dose were unknown and were not included in the analysis. Moreover, patients after isolated cardiac valve surgery may undergo a different inflammatory and oxidative response than patients after reperfusion surgery (Bolesta and Kong 2015) .
A recent meta-analysis (Razaei et al., 2016), which included 12 randomized controlled trials (RCTs) involving 1116 patients, indicated that perioperative statin therapy in statin-naive patients with sinus rhythm undergoing cardiac surgery led to a decrease in the development of POAF, the hospital length of stay (LOS), and the CRP level. Moreover, it was found that the beneficial effects on AF occurrence and CRP level were more marked in patients receiving atorvastatin compared to other statins (Razaei et al., 2016).
In patients undergoing non-transplant cardiac surgery, pre-operative use of statins has proven to be beneficial in many studies. However, data on the influence of pre-operative statin therapy in heart transplant surgery are lacking. A recent retrospective study on the influence of pre-transplant statin treatment on clinical outcomes after heart transplantation indicated that pre-operative statin therapy does not seem to influence the risk of mortality or early POAF after heart transplantation (Krishnan et al., 2016) . These are preliminary findings, which should be confirmed by further large-scale prospective clinical studies. 2015) showed that statin therapy was associated with lower risk of newly diagnosed AF in dialysis patients. The authors of that study observed a significant dose-dependent inverse association between new-onset AF and statin use for total accumulated doses. The protective effect was especially seen among patients who received the highest total statin dosage.
Type and dose of statin in atrial fibrillation
The exact difference of different types of statin in preventing POAF occurrence has not been sufficiently investigated. Atorvastatin is a highly effective statin and is the most studied statin in relation to AF (Fauchier et Advanced age is indicated as a major risk factor for the development POAF after cardiac surgery (Mathew at al., 1996) . Data on whether pre-operative statin therapy is beneficial in advanced age patients on POAF occurrence is lacking. Recently, Kunt et al. (2015) demonstrated no influence of pre-treatment with atorvastatin in doses of 20 and 40 mg on AF reduction after cardiac surgery in patients aged over seventy years. The authors also found no association between dose and duration of statin therapy for the development of POAF (Kunt et al., 2015) .
Results concerning the influence of the dose of atorvastatin on POAF occurrence are also conflicting. Some studies indicate that higher dose statins have a greater preventive effect, in comparison to low-dose statins (Lertsburapa et al., 2008) , while others report opposite findings (Wang et al., 2011) . There are also studies which found equal benefits of high and low dosage of statins in prevention of AF (Karimi et al., 2012) . Pierri et al. (2016) studied the influence of seven-day preoperative treatment with two different dosages of atorvastatin on the incidence of POAF in 212 patients undergoing elective first-time on-pump CABG. The authors reported that comparing treatment with 80 mg and 40 mg of atorvastatin, the higher dosage group had lower incidence of POAF but the difference was not significant. Moreover, there was no significant difference between the treatment of these two dosages of statin and the level of hsCRP and interleukin-6 (IL-6) at 12 and 24 h. The recent study of Zheng et al. (2016) indicated that perioperative rosuvastatin therapy at a dose of 20 mg daily did not prevent POAF in patients undergoing elective CABG and was associated with an increased risk of postoperative acute kidney injury (Zheng et al., 2016) . The results of this trial are inconsistent with the previous studies. It could be explained by short duration of preoperative treatment, which might have decreased the pleiotropic effects of statin therapy (Barakat et al., 2016) .
One of the factors which could influence the beneficial effect of preoperative statin therapy on POAF is the duration of statin therapy. Some studies have suggested that statins reveal their full pleiotropic effect in 14 days of treatment (Barakat et al., 2016a) . Meta-regression analysis indicated that preoperative statin use was associated with a 3% reduction in the risk of POAF per day of therapy (Chen et al., 2010) .
Conclusions
Until now, the strongest evidence for AF prevention by statin therapy is in post-cardiac surgery patients. Recently published studies on the use of statins against AF have focused mainly on the prevention of AF after cardiac surgery. Most studies have confirmed the decrease in occurrence of post-operative AF with pre-operative therapy. Despite the increasing number of studies on this issue, the mechanism of pre-operative statin treatment on POAF incidence reduction is still not fully elucidated. The hypothetical mechanism of action of statins might be associated with their anti-inflammatory and antioxidant properties (Adam et al., 2008) .
The effect of statin on postoperative AF might depend on many factors including type of statin and dosage. The difference in impact of different types and doses of statins on AF is not fully clear. Statin therapy is recommended to be started approximately 14 days before surgery (Elgendy et al., 2015) .
